Felix Hsu has been appointed senior vice president of WuXi AppTec U.S. In his new role, Mr. Hsu will be responsible for WuXi’s U.S. business. He will report to Edward Hu, chief operating officer, acting chief financial officer, and current head of U.S. operations.

Prior to joining WuXi, Mr. Hsu worked at Medtronic for 14 years in positions of increasing responsibility. He has broad experience as a product manager and business leader, serving as director of Heart Valve Worldwide Marketing; vice president of Business Excellence; vice president of Cardiac Surgery for Asia Pacific, based in Hong Kong; and vice president of Supply Chain Integration based in Minneapolis. Prior to working at Medtronic, he served in product management, sales management, and strategic planning roles at Abbott Laboratories and as a business manager at Sabratek.

“I am very pleased to welcome Felix on board as we continue to strengthen our U.S. management team,” commented Dr. Ge Li, chairman and chief executive officer of WuXi PharmaTech. “Our U.S. operations offer a range of testing services critical to the successful development and regulatory approval of new biologics and medical devices. We expect our U.S. business will grow under Felix’s leadership.”

Wei-Min Chang has been appointed vice president of operations and general manager of the company’s SynTheAll (STA) manufacturing facility, located in the Jinshan chemical industry zone of Shanghai. Mr. Chang will report to Dr. Li. Dr. Eric Gu, who previously held those roles, has been appointed vice president of business development for Manufacturing Services, reporting to Dr. Suhan Tang, chief manufacturing officer.

The SynTheAll facility manufactures APIs and advanced intermediates for use in preclinical and clinical trials. The company recently completed construction of an expanded facility, known as SynTheAll Phase 2, to produce advanced intermediates and APIs for late-stage clinical trials and commercial supplies. This new facility is expected to open in stages, beginning in late 2009.

Prior to joining WuXi, Mr. Chang worked at Eastbound Synopharma (HK) Holding Co. as vice president of Chemical Development, responsible for research and development, small-scale manufacturing, quality control/quality assurance, regulatory affairs and other general administrative functions at Eastbound Shanghai Institute. From 1999 to 2006, he worked for Taiwan Biotech as the company’s head of U.S. operations and as vice president of R&D/Quality/Regulatory Affairs/API Operations. From 1989 to 1998, he was senior process engineer/chemical engineer at Eli Lilly, where he was responsible for designing and developing manufacturing processes for advanced intermediates, APIs, and bulk pharmaceuticals at both laboratory and pilot plant scale.

“We are delighted to have someone with Mr. Chang’s extensive manufacturing experience to manage our Jinshan facility,” said Dr. Li. “Wei-Min’s knowledge of cGMP manufacturing operations within the pharmaceutical, biotechnology, and chemical industries will help WuXi manage its manufacturing facilities efficiently and effectively.”